Peptide quality involves more than simply confirming purity and molecular weight. A peptide’s amino-acid sequence, stereochemistry, chemical modifications, folding, and ability to adopt the proper three-dimensional conformation can all influence how effectively it binds to and activates its intended receptor. Problems such as D-amino-acid substitutions, sequence errors, oxidation, aggregation, or incorrect disulfide bonding may reduce biological activity.
Common testing such as HPLC and LC-MS is extremely valuable, but it has limitations. HPLC primarily measures purity, while LC-MS helps confirm molecular mass and identity. These tests do not directly demonstrate that the peptide binds its receptor or produces the expected biological response. A product could appear highly pure and have the expected mass yet still possess lower-than-expected potency. “Biological availability” is sometimes used to describe this issue, but “biological activity” or “potency” is more scientifically accurate.
I would love to see Peptide Critic conduct a blinded experiment using products purchased randomly from several vendors. Each sample could receive the usual HPLC and LC-MS testing, followed by an appropriate receptor-binding or cell-based functional assay. Testing the pharmaceutical reference standard alongside them would make the comparison especially meaningful.
This would help answer an important question: Do products that pass routine purity and identity testing consistently produce the expected biological response? Even a small pilot study could provide valuable real-world information and show whether additional functional testing should become part of independent peptide evaluation.
Charles River Laboratories. They specifically advertise cell-based functional testing for GLP-1, GIP and glucagon receptor agonists, including measurements of potency and receptor selectivity—an especially good fit for retatrutide or tirzepatide.